Literature DB >> 9384236

Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats.

J Kiss1, D Lamarque, J C Delchier, B J Whittle.   

Abstract

The time-dependent actions following pretreatment or delayed administration of the nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME) on colonic inflammation and inducible NO synthase activity following the intrarectal administration of trinitrobenzene sulphonic acid (TNBS) were evaluated in the rat. Intracolonic instillation of TNBS (30 mg in 0.25 ml of 50% ethanol) led to macroscopic injury, an increase of mucosal myeloperoxidase activity and the expression of the Ca2+-independent inducible NO synthase over 8 days. The inflammatory response following TNBS reached maximum levels between 12 and 72 h and then it declined until 14 days. Oral administration of L-NAME (25 mg/kg per 24 h in the drinking water) 2 days before TNBS augmented macroscopic damage and increased colonic inducible NO synthase activity 6, 12, 24 and 72 h after TNBS administration. In contrast, when L-NAME was administered 6 h after TNBS instillation, at time of expression of inducible NO synthase, the macroscopic lesions were reduced, as well as the enhanced inducible NO synthase activity, determined, over 72 h. Delayed (6 h after TNBS) administration of L-NAME also attenuated the colonic myeloperoxidase activity provoked by TNBS, after 24 h. This activity was not affected by pretreatment (2 days before TNBS) with L-NAME. These findings indicate that the timing of administration of non-selective NO synthase inhibitors such as L-NAME, in models of colitis is critical to the eventual outcome. Thus, pretreatment with L-NAME, which will inhibit constitutive NO synthase, exacerbates the subsequent damage following challenge. In contrast, delayed administration of L-NAME at the time of inducible NO synthase expression, has a beneficial action on the colonic injury and inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384236     DOI: 10.1016/s0014-2999(97)01246-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Induction of iNOS in a rat model of acute colitis.

Authors:  E Kankuri; M Z Asmawi; R Korpela; H Vapaatalo; E Moilanen
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

3.  Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase.

Authors:  B Zingarelli; C Szabó; A L Salzman
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

4.  Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta.

Authors:  Brendan J R Whittle; Csaba Varga; Anikó Pósa; Andor Molnár; Marika Collin; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 5.  Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle.

Authors:  George Kolios; Vassilis Valatas; Stephen G Ward
Journal:  Immunology       Date:  2004-12       Impact factor: 7.397

Review 6.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.